Hartford Healthcare | Cancer Clinical Research Office

Research site

(Unclaimed)

Location

80 Seymour Street, P.O. Box 5037, Hartford, Connecticut, United States of America

Site insights

Top conditions

Top treatments

Nivolumab

CMP-001

Capecitabine

risperidone

VB-111

Labetalol

Dostarlimab

Bevacizumab

capecitabine

5-FU

Parent organization

This site is a part of Hartford Healthcare

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 35 total trials

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Enrolling

Myelofibrosis

Drug: Imetelstat

Drug: Best Available Therapy (BAT)

Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure...

Enrolling

Diastolic Heart Failure

Heart Failure With Preserved Ejection Fraction

Device: OPTIMIZER™ Smart Mini System

Device: Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System

Assessment of Combined CCM and ICD Device in HFrEF (INTEGRA-D)

The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert indu...

Enrolling

Heart Failure with Reduced Ejection Fraction

CCM Therapy

Device: OPTIMIZER® Integra CCM-D System (Treatment Arm)

Medtronic Terminate AF Study

The purpose of this study is to demonstrate the safety and effectiveness of the Cardioblate iRF and CryoFlex hand held devices for the treatment of n...

Enrolling

Persistent Atrial Fibrillation

Longstanding Persistent Atrial Fibrillation

Procedure: Surgical Ablation

Device: Cardioblate and Cryoflex hand held devices

NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness (TRIOMPHE)

Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic...

Enrolling

Intramural Hematoma

Penetrating Aortic Ulcer

Device: NEXUS Aortic Stent Graft System

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting

Solid Tumor

Malignant Neoplasm

Drug: nab-sirolimus

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine...

Enrolling

Solid Tumor

Rectal Adenocarcinoma

Drug: capecitabine or 5-FU

Drug: TSR-042 or Dostarlimab

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short. Tamibarotene i...

Active, not recruiting

Acute Myeloid Leukemia

Drug: Azacitidine

Drug: Venetoclax

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotact...

Enrolling

Non-small Cell Lung Cancer Stage II

PD-L1 Gene Mutation

Radiation: Stereotactic Body Radiation Therapy

Drug: Durvalumab